23 November 2026 | Monday | Interaction
Editor: BioPharma Boardroom
Children living with activated PI3K delta syndrome (APDS) face recurrent infections, immune dysfunction and potentially serious long-term complications. Pharming has received UK approval to extend Joenja (leniolisib) to children aged 4–11 years weighing at least 27 kg, offering an earlier treatment option for this rare immune disorder. BioPharma Boardroom speaks with Leverne Marsh, BPharm, Interim Co-CEO and Chief Commercial Officer, Pharming about the clinical evidence supporting the approval, challenges in early diagnosis, NHS access and plans to expand treatment availability internationally
Q. The MHRA has approved Joenja for children aged 4 to 11 years weighing at least 27 kg, making it the first treatment specifically approved for pediatric APDS patients in the U.K. What does this approval mean for Pharming, and how important is it for families who previously had to wait until their children were older to access an approved targeted therapy?
The MHRA approval extends the existing U.K. indication for Joenja to children aged 4 to 11 years who weigh at least 27 kg, providing eligible younger patients with an approved targeted treatment option. This is an important milestone for families given the progressive nature of APDS and the potential for serious long-term complications. Joenja is expected to become available to these patients in February 2027, and we will work closely with the NHS and relevant stakeholders to support timely access
Progress in rare disease care is built on collaboration. Patients and caregivers help us understand the disease burden and the unmet needs, while clinical investigators, specialist physicians and regulators contribute to building and assessing the evidence for new treatments. At Pharming, we bring together our scientific, medical, regulatory and commercial expertise to translate these collective efforts into meaningful progress for patients
Q. APDS is a progressive immune disorder that can lead to recurrent infections, immune dysregulation, and serious long-term complications. Why is starting targeted treatment at a younger age particularly important, and what difference could earlier intervention make to the lives of children living with this condition?
APDS can manifest early in childhood and is associated with a range of symptoms, including recurrent infections, lymphoproliferation and autoimmunity. As a progressive disease, it can lead to serious long-term complications, including permanent organ damage.
The expanded indication allows physicians and families to consider an approved treatment targeting the underlying dysregulated pathway earlier in a child's life. While the long-term impact of earlier intervention requires continued clinical follow-up, having an approved treatment option before the age of 12 is an important development for eligible families.
Living with a rare disease can affect many aspects of childhood, from attending school to participating in everyday activities, while also placing a considerable emotional and practical burden on caregivers.
This is why we believe earlier intervention needs to be considered in the context of the entire patient journey, from disease recognition and timely diagnosis to specialist care and access to targeted treatment. By listening to patients, families, and healthcare professionals, we can better understand the challenges they face and help address the barriers to receiving appropriate treatment earlier in life.
Q. The approval was supported by Pharming's pediatric clinical program, along with additional safety and clinical pharmacology assessments. What were the most important findings that supported extending Joenja to younger children, and how did you establish appropriate dosing for patients in this age group?
Developing medicines for pediatric populations in ultra-rare diseases presents unique challenges. Patient populations are small, clinical manifestations can vary considerably, and dosing must be supported by evidence appropriate to the age and weight of the patients.
The MHRA decision was supported by data from our pediatric clinical program, conducted as part of the MHRA-agreed Pediatric Investigation Plan, alongside additional safety and clinical pharmacology assessments.
Our pediatric Phase III study demonstrated improvements over 12 weeks in clinically relevant measures of APDS, including lymphadenopathy and the proportion of naïve B cells. Leniolisib was generally well tolerated in patients aged 4 years and older. The additional assessments supported the authorized twice-daily doses of 40 mg and 50 mg for eligible children aged 4 to 11 years weighing at least 27 kg.
As we expand our existing portfolio and advance our pipeline, this evidence-driven approach remains central to our work. Our responsibility is to pursue scientific innovation while maintaining the high standards of evidence, safety and transparency that patients and healthcare professionals expect from us.
Q. Joenja is expected to become available to eligible younger patients in the U.K. in February 2027. What steps is Pharming taking with the NHS to prepare for this launch, and what challenges could arise in ensuring that children who qualify for treatment can access it without unnecessary delays?
Our responsibility is to ensure that scientific and regulatory progress translates into timely and appropriate access to innovative medicines for patients. We will work closely with the NHS and relevant stakeholders to facilitate timely access for eligible children, ahead of the anticipated availability of Joenja under the expanded indication in February 2027.
In APDS, regulatory and reimbursement approvals are critical milestones, but our work extends to addressing the often-lengthy journey patients and families face from symptoms to treatment. We are strengthening our educational efforts to help patients receive an accurate diagnosis earlier, navigate referral pathways more efficiently, and access appropriate treatment sooner. We are also providing patients and caregivers with clear information and ongoing support to help them start and stay on treatment as prescribed.
For me, this is what commercial excellence in rare disease is about: understanding the barriers that patients face and working collaboratively to address them. As we expand our international presence, we want to build on our experience while remaining responsive to local needs and healthcare priorities.
Q. APDS is estimated to affect just one to two people per million worldwide, and patients can face diagnostic delays of several years because symptoms overlap with other immune disorders. What needs to change in clinical awareness and genetic testing practices to identify affected children earlier, particularly before irreversible complications develop?
Published research has reported a median diagnostic delay of seven years for APDS. Its symptoms frequently overlap with those of other primary immunodeficiencies, meaning patients may consult multiple specialists before receiving an accurate diagnosis. Genetic testing for disease-causing variants in PIK3CD or PIK3R1 can establish a definitive diagnosis.
Improving awareness among pediatricians, immunologists, and other healthcare professionals who may encounter these patients is essential. Recognizing patterns of recurrent infections, lymphoproliferation, and immune dysregulation can help facilitate earlier specialist referral and appropriate genetic testing. While the patient identification journey varies from country to country, reflecting differences in healthcare systems, disease awareness and diagnostics practices, we are encouraged by the positive momentum we are seeing across our international markets in identifying patients who may have previously remained undiagnosed.
As of September 30, 2026, we identified 1,056 diagnosed APDS patients globally. We continue to focus on improving disease recognition and identifying patients who may otherwise remain undiagnosed.
This challenge extends well beyond APDS. Across rare diseases, patients and families often experience a prolonged diagnostic journey before they understand the underlying cause of their condition.
Advancing our understanding of disease biology, strengthening collaboration across the rare disease community, and supporting disease awareness are important components of our broader strategy. By combining scientific innovation with commercial expertise and engagement with healthcare professionals, we aim to help address unmet needs at different stages of the patient journey.
Q. Pharming has described this approval as part of its wider strategy to expand Joenja across age groups and international markets. Which regulatory and clinical milestones are next for the treatment, and how do you plan to extend access to younger APDS patients in other countries?
In addition to the U.K. approval, we have expanded the U.S. indication for Joenja to eligible children aged 4 to 11 years weighing at least 27 kg, and in August 2026, Joenja became commercially available in Japan for patients aged four years and older
Our next regulatory milestone is the FDA’s decision on lower doses for pediatric patients weighing between 13 kg and less than 27 kg, with a PDUFA target action date of January 30, 2027.
We will continue to pursue opportunities to expand access in key international markets, taking into account local regulatory requirements, healthcare systems, and patient needs.
Beyond APDS, we are evaluating leniolisib in additional primary immunodeficiencies associated with immune dysregulation, with the ambition to address unmet medical needs in broader patient populations. Leniolisib remains investigational in these indications.
We are also advancing napazimone (KL1333), for primary mitochondrial disease, with enrollment in the pivotal FALCON study expected to be completed in the first half of 2027.
Together, our established commercial portfolio, the continued expansion of Joenja and our advancing pipeline reflect Pharming's evolution as a global rare disease company. Our ambition is to build a sustainable business that can continue investing in scientific innovation, extend the reach of our medicines, and address the needs of more patients living with rare diseases. Ultimately, that is what drives our strategy and our decisions.
© 2026 Biopharma Boardroom. All Rights Reserved.